The diagnostic and prognostic significance of a targeted plasma nCounter developed non-invasive marker panel in colorectal cancer patients
Project Name in Chinese
靶質血漿計數器在結腸直腸癌患者中開發的非侵入性標記面板的診斷和預後意義
Brief description of the Project
The potential applications of novel gene panels for non-invasive diagnosis, prognosis and therapeutics in patients with colorectal cancer. The aim of this project is to develop a non-invasive diagnostic and prognostic strategy using a targeted plasma nCounter developed marker panel to predict tumor recurrence, metastasis and survival in colorectal cancer patients.
Academic Discipline of the Research Project
Molecular Diagnostics
Academic Discipline (specifically) in Chinese
1010 醫學技術
Is this an inter-disciplinary project ?
Yes
Discipline 1)
Biomedical Technology
Academic Discipline (specifically) in Chinese
0831 生物醫學工程
Discipline 2)
Molecular Diagnostics
Academic Discipline (specifically) in Chinese
1010 醫學技術
Special Requirement for the Postdoctoral Fellow Candidates(if any)
Experience in high throughput molecular techniques such as real-time PCR, digital PCR, next generation sequencing.
Academic Qualifications
PhD, MAppSc, BAppSc
Professional Accomplishments, Honors, Awards and Patents
Founding Fellow (Faculty of Science), The Royal College of Pathologists of Australasia.
Fellow, the Hong Kong Society of Molecular Diagnostics.
Are you a member of the Society of Hong Kong Scholars?
Yes
Research direction and research fund
Major Research Interests
Development of non-invasive cancer biomarkers with diagnostic and prognostic significance for Asian common cancers such as colorectal cancer, cervical cancer, nasopharyngeal cancer and their pre-malignant states
Number of Current PhD Students
1
Number of PhD Trained
4
Number of Postdoctoral Fellows Supervised
4
Active Research Grants in the Capacity of PI
1) General Research Fund, Research Grants Council, Hong Kong, 2019: The diagnostic significance of CDH17-positive circulating tumor cells and therapeutic implication of targeting CDH17 protein in colorectal cancer. (HK$897,465)
2) Innovation and Technology Research Fund, 2018: ARB-101 monoclonal antibody targeted therapy against malignant gastrointestinal cancers: Proof of concept study. (HK$2,300,000)
3) Novel Research Grant, The Hong Kong Anti-Cancer Society, 2016: Diagnostic significance of plasma targeted mRNAs using NanoString nCounter technology in colorectal cancer patients. (HK$179,900)
4) Collaborative Research Fund, Research Grants Council, Hong Kong, 2014: Micro-PET for pre-clinical molecular imaging research in Hong Kong. (Co-Principal Investigator: HK$4,000,000)
5) Health and Medical Research Fund, Food and Health Bureau, 2014: The diagnostic and prognostic usefulness of a targeted plasma RNA sequencing developed non-invasive marker panel in colorectal cancer. (HK$935,302)